Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Jun 2024)

Phenotypic Clusters and Multimorbidity in Hypermobile Ehlers-Danlos Syndrome

  • Taylor Petrucci, BS,
  • S. Jade Barclay, MPH,
  • Cortney Gensemer, PhD,
  • Jordan Morningstar, BS,
  • Victoria Daylor, BFA,
  • Kathryn Byerly, BS,
  • Erika Bistran, BS,
  • Molly Griggs, MEd,
  • James M. Elliott, PhD,
  • Teresa Kelechi, RN, PhD,
  • Shannon Phillips, RN, PhD,
  • Michelle Nichols, RN, PhD,
  • Steven Shapiro, DMD, MD,
  • Sunil Patel, MD,
  • Nabila Bouatia-Naji, PhD,
  • Russell A. Norris, PhD

Journal volume & issue
Vol. 8, no. 3
pp. 253 – 262

Abstract

Read online

Objective: To perform a retrospective clinical study in order to investigate phenotypic penetrance within a large registry of patients with hypermobile Ehlers-Danlos syndrome (hEDS) to enhance diagnostic and treatment guidelines by understanding associated comorbidities and improving accuracy in diagnosis. Patients and Methods: From May 1, 2021 to July 31, 2023, 2149 clinically diagnosed patients with hEDS completed a self-reported survey focusing on diagnostic and comorbid conditions prevalence. K-means clustering was applied to analyze survey responses, which were then compared across gender groups to identify variations and gain clinical insights. Results: Analysis of clinical manifestations in this cross-sectional cohort revealed insights into multimorbidity patterns across organ systems, identifying 3 distinct patient groups. Differences among these phenotypic clusters provided insights into diversity within the population with hEDS and indicated that Beighton scores are unreliable for multimorbidity phenotyping. Conclusion: Clinical data on the phenotypic presentation and prevalence of comorbidities in patients with hEDS have historically been limited. This study provides comprehensive data sets on phenotypic presentation and comorbidity prevalence in patients with hEDS, highlighting factors often overlooked in diagnosis. The identification of distinct patient groups emphasizes variations in hEDS manifestations beyond current guidelines and emphasizes the necessity of comprehensive multidisciplinary care for those with hEDS.